DOWNSTREAM PROCESSING FEATURED ARTICLES
Mayo Clinic researchers have successfully used smaller, folded DNA molecules to stimulate regeneration and repair of nerve coatings in mice that mimic multiple sclerosis (MS). They say the finding, published today in the journal PLoS ONE, suggests new possible therapies for MS patients.
-
Research Breakthrough Selectively Represses The Immune System
In a mouse model of multiple sclerosis (MS), researchers funded by the National Institutes of Health have developed innovative technology to selectively inhibit the part of the immune system responsible for attacking myelin -- the insulating material that encases nerve fibers and facilitates electrical communication between brain cells.
-
Ablynx And Its Partner Advance Nanobody Candidate ALX-0751 In Pre-Clinical Development
Ablynx [Euronext Brussels: ABLX] today announced that they have advanced the Nanobody(®) candidate ALX-0751, together with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, into pre-clinical development in the field of oncology.
-
Combo Of Avastin, Second Drug Shows Promise Fighting Brain Cancer, Mayo Clinic Finds
The drug bevacizumab, also known by the trade name Avastin, shrinks tumors briefly in patients with an aggressive brain cancer known as glioblastoma multiforme, but then they often grow again and spread throughout the brain for reasons no one previously has understood.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
USP <787> Small Volume Testing With Liquid Particle Counters
By their very nature, biological therapeutics are not only expensive to manufacture but are often produced in small volumes.
-
Examining Column Reproducibility During Method Development In Clinical Labs
In this study demonstrates how the HSS T3 stationary phase is a reliable stationary phase, as three batches made over a five-year span provide comparable results.
-
A Purification Strategy For Clinical-Grade Monoclonal Antibody
mAbs are currently the most important class of therapeutic proteins. Advances in upstream process technologies have led to tremendous improvement of mAb titers in mammalian cell culture.
-
Improving DNA Removal from Bioprocess Purification Processes
Many new biological drug products produced using recombinant DNA technology, such as monoclonal antibodies, are produced in cell culture. Because therapeutic proteins such as monoclonal antibodies are produced in cell culture, impurities can result from the host cells, or cell substrates. By 3M Purification Inc.
-
Compound Profiling And Toxicity
Utilizing a systems approach to drug discovery has generated a multitude of high affinity compounds for various classes of molecular targets with different degrees of disease state validation.
-
Optimized Sterile Filtration of Pharmaceutical Solutions
The cost of filtration and separation stages within the production of pharmaceuticals has been increasing along with the increased complexity of final drug products.